Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review

European Urology

Volumn 70, Issue 3, 2016, Pages 416-426

  Jong van Dodewaard de, Joyce M ^a   Oprea Lager, Daniela E ^a   Hooft, Lotty ^b   de Klerk, John M H ^c   Bloemendal, Haiko J ^c   Verheul, Henk M W ^a   Hoekstra, Otto S ^a   van den Eertwegh, Alfons J M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Bone metastases; Bone pain; Bone seeking radiopharmaceutical; Prostate cancer

Indexed keywords

ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; STRONTIUM CHLORIDE SR 89; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ETIDRONIC ACID; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE; RADIUM; RHENIUM-186 HEDP; SAMARIUM SM-153 LEXIDRONAM; STRONTIUM; STRONTIUM CHLORIDE;

BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; LEUKOPENIA; MEDLINE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; BONE TUMOR; COMPLICATION; MALE; PALLIATIVE THERAPY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; SECONDARY;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CANCER PAIN; ETIDRONIC ACID; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PALLIATIVE CARE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRONTIUM; STRONTIUM RADIOISOTOPES;

EID: 84942032960     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.09.005     Document Type: Review

References (49)

1. [1] Saad, F., Clarke, N., Colombel, M., Natural history and treatment of bone complications in prostate cancer. Eur Urol 49 (2006), 429–440.
2. [2] Van Dodewaard-de Jong, J.M., Verheul, H.M.W., Bloemendal, H.J., de Klerk, J.M., Carducci, M.A., van den Eertwegh, A.J., New treatment options for patients with metastatic prostate cancer: what is the optimal sequence?. Clin Genitourin Cancer 13 (2015), 271–279.
3. [3] Mercadente, S., Malignant bone pain: pathophysiology and treatment. Pain 69 (1997), 1–18.
4. [4] Ripamonti, C., Fulfaro, F., Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 4 (2000), 187–196.
5. [5] Lam, M.G.E.H., de Klerk, J.M.H., van Rijk, P.P., Zonnenberg, B.A., Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem 7 (2007), 381–397.
6. [6] Roqué, I., Figuls, M., Martinez-Zapata, M.J., Scott-Brown, M., Alonso-Coello, P., Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev, 6, 2011, CD003347.
7. 89 chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Eur Urol 44 (2003), 519–526.
8. [8] Windsor, P.M., Predictors of response to Strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin Oncol 13 (2001), 219–227.
9. [9] Turner, S.L., Gruenewald, S., Spry, N., Gebski, V., Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84 (2001), 297–302.
10. [10] Quilty, P.M., Kirk, D., Bolger, J.J., et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31 (1994), 33–40.
11. 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. Br J Cancer 66 (1992), 177–180.
12. [12] Lewington, V.J., McEwan, A.J., Ackery, D.M., et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27 (1991), 954–958.
13. [13] Laing, A.H., Ackery, D.M., Bayly, R.J., et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 64 (1991), 816–822.
14. [14] Buchali, K., Correns, H.J., Schuerer, M., Schnorr, D., Lips, H., Sydow, K., Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14 (1988), 349–351.
15. [15] Robinson, R.G., Spicer, J.A., Preston, D.F., et al. Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 14 (1987), 219–222.
16. 89Strontium therapy of bone metastases of carcinoma of the prostatic gland. Eur J Nucl Med 4 (1979), 33–35.
17. [17] Ripamonti, C., Fagnoni, E., Campa, T., Seregni, E., Maccauro, M., Bombardieri, E., Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer 15 (2007), 339–342.
18. [18] Tripathi, M., Singhal, T., Chandrasekhar, N., et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer 43 (2006), 86–92.
19. 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases. Neoplasma 60 (2013), 328–333.
20. [20] Sartor, O., Reid, R.H., Hoskin, P.J., et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63 (2004), 940–945.
21. [21] Serafini, A.N., Houston, S.J., Resche, I., et al. Palliation of pain associated with metastatic bone cancer using Samarium-153 Lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16 (1998), 1574–1581.
22. 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33 (1997), 1583–1591.
23. [23] Collins, C., Eary, J.F., Donaldson, G., et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34 (1993), 1839–1844.
24. 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases. Eur J Nucl Med Mol Imaging 37 (2010), 103–113.
25. 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging. 33 (2006), 1055–1061.
26. 186Re-Etidronate in hormone-resistant prostate cancer patients with painful bone metastases. J Nucl Med 43 (2002), 1150–1156.
27. 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 41 (2000), 1689–1694.
28. [28] Tennvall, J., Abrahamsson, P.A., Ahlgren, G., et al. Palliative radiation with a radiolabeled diphosphonate (Rhenium-186 Etidronate) in patients with hormone-refractory disseminated prostate carcinoma. Scand J Urol Nephrol 34 (2000), 188–193.
29. 186Re-1,1-hydroxyehtylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 41 (2000), 647–654.
30. [30] Giannakenas, C., Kalofonos, H.P., Apostolopoulos, D.J., Zarakovitis, J., Kosmas, C., Vassilakos, P.J., Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol 23 (2000), 83–88.
31. [31] Israel, O., Keidar, Z., Rubinov, R., et al. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. J Clin Oncol 18 (2000), 2747–2754.
32. [32] Limouris, G.S., Shukla, S.K., Manetou, A., et al. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer. Anticancer Res 17 (1997), 1699–1704.
33. [33] Schoeneich, G., Palmedo, H., Heimbach, D., Biersack, H.J., Müller, S.C., Advanced prostate cancer: systemic radiopharmaceutical therapy of metastatic prostate cancer with rhenium-186 hydroxyethylidene diphosphonate. Onkologie 20 (1997), 316–319.
34. [34] Quirijnen, J.M.S.P., Han, S.H., Zonnenberg, B.A., et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 37 (1996), 1511–1515.
35. [35] Maxon, H.R. III, Schroder, L.E., Thomas, S.R., et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 176 (1990), 155–159.
36. [36] Liepe, K., Kropp, J., Runge, R., Kotzerke, J., Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89 (2003), 625–629.
37. [37] Palmedo, H., Manka-Waluch, A., Albers, P., et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomised phase II trial with the new, high-energy radiopharmaceutical rhenium-188-hydroxyethylidenediphosphonate. J Clin Oncol 21 (2003), 2869–2875.
38. [38] Parker, C.C., Pascoe, S., Chodacki, A., et al. A randomised, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63 (2013), 189–197.
39. [39] Nilsson, S., Strang, P., Aksnes, A.K., et al. A randomised, dose-response, multicentre phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 48 (2012), 678–686.
40. 153Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 28 (2007), 245–250.
41. [41] Dafermou, A., Colamussi, P., Giganti, M., Cittanti, C., Bestagno, M., Piffanelli, A., A multicentre observational study of radionuclide therapy in patients with painful bone metastases or prostate cancer. Eur J Nucl Med 28 (2001), 788–798.
42. [42] Liepe, K., Runge, R., Kotzerke, J., The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 131 (2005), 60–66.
43. [43] Parker, C., Nilsson, S., Heinrich, D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 (2013), 213–223.
44. [44] Morris, M.J., Pandit-Taskar, N., Carrasquillo, J., et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27 (2009), 2436–2442.
45. [45] Fizazi, K., Beuzeboc, P., Lumbroso, J., et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27 (2009), 2429–2435.
46. [46] Tu, S.M., Mathew, P., Wong, F.C., Jones, D., Johnson, M.M., Logothetis, C.J., Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 27 (2009), 3319–3324.
47. 186Re-HEDP in castration-resistant prostate cancer (CRPC) to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging 38 (2011), 1990–1998.
48. [48] Dworkin, R.H., Turk, D.C., Peirce-Sandner, S., et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 153 (2012), 1148–1158.
49. [49] Dworkin, R.H., Turk, D.C., Wyrwich, K.W., et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9 (2008), 105–121.